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Background: Treatment of patients with stage pT1 urothelial bladder cancer (UBC) continues to be a challenge
due to its unpredictable clinical course. Reliable molecular markers that help to determine appropriate individual
treatment are still lacking. Loss of aquaporin (AQP) 3 protein expression has previously been shown in
muscle-invasive UBC. The aim of the present study was to investigate the prognostic value of AQP3 protein
expression with regard to the prognosis of stage pT1 UBC.
Method: AQP 3 protein expression was investigated by immunohistochemistry in specimens of 87 stage T1 UBC
patients, who were diagnosed by transurethral resection of the bladder (TURB) and subsequent second resection at
a high-volume urological centre between 2002 and 2009. Patients underwent adjuvant instillation therapy with
Bacillus Calmette-Guérin (BCG). Loss of AQP3 protein expression was defined as complete absence of the protein
within the whole tumour. Expression status was correlated retrospectively with clinicopathological and follow-up
data (median: 31 months). Multivariate Cox regression analysis was used to assess the value of AQP3 tumour
expression with regard to recurrence-free (RFS), progression-free (PFS) and cancer-specific survival (CSS). RFS, PFS
and CSS were calculated by Kaplan-Meier analysis and Log rank test.
Results: 59% of patients were shown to exhibit AQP3-positive tumours, whereas 41% of tumours did not express
the marker. Loss of AQP3 protein expression was associated with a statistically significantly worse PFS (20% vs. 72%,
p=0.020). This finding was confirmed by multivariate Cox regression analysis (HR 7.58, CI 1.29 – 44.68; p=0.025).
Conclusions: Loss of AQP3 protein expression in pT1 UBC appears to play a key role in disease progression and is
associated with worse PFS. Considering its potential prognostic value, assessment of AQP3 protein expression could
be used to help stratify the behavior of patients with pT1 UBC.
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Being a matter of debate for more than 100 years, the
molecular basis of water transport across epithelial sur-
faces was first described in red blood cells in the late
1980s by Peter Agre and associates [1]. Later on, water-
transporting channels were also shown to be present in
renal epithelial cells and subsequently termed aquapor-
ins (AQP) [2-4]. AQPs are a family of transmembrane
proteins that selectively allow water or water plus other
small, uncharged molecules such as urea and glycerol to
pass along hydrostatic and osmotic gradients. Aquapor-
ins are ubiquitously expressed in bacterial, animal and
human cells. Hence, they are essential for cellular func-
tion [5]. To date, 13 different mammalian AQPs have
been identified at the molecular level and localised to
particular tissues [6]. Analysis of several human diseases
has confirmed that AQPs are involved in various patho-
logical conditions and provide promising drug targets
[7,8]. Moreover, there is strong presumptive evidence
that AQPs play a role in carcinogenesis, specifically
in tumour angiogenesis and cell migration [9]. The
pro-tumourigenic effect of a lost AQP expression in
neoplastic cells has been the subject of previous studies.
Knockdown of AQP3 for instance has been shown to be
associated with increased migration and proliferation of
gastric cancer cells [10].
There is only very limited data on expression and bio-
logical significance of aquaporins in human urothelium.
Rubenwolf et al. were the first to characterize human
urothelium with regard to all 13 members of the human
AQP family. While transcripts for AQP3, AQP4, AQP7,
AQP9 and AQP11 were detected in freshly-isolated
urothelium and cultured urothelial cells by reverse
transcriptase-polymerase chain reaction (RT-PCR), AQP3
was unequivocally expressed also at the protein level, with
intense immunohistochemical labelling of the cell mem-
branes of basal and intermediate layers in normal bladder
urothelium [11].
To date, investigations into the potential significance
of aquaporins in urothelial bladder carcinoma (UBC) are
lacking [12]. In a preliminary analysis of AQP3 expres-
sion in UBC of various stages, our group demonstrated
loss of AQP3 in muscle-invasive disease whereas stage
Ta specimens were shown to invariably express the mar-
ker. Interestingly, 60% of pT1 tumours were found to be
AQP3 positive while the remaining specimens revealed
complete absence of AQP3. This finding suggests that
AQP3 could be of value as a prognostic marker, particu-
larly in the highly heterogeneous subgroup of pT1
patients [13]. The objective of the present study was to
analyze the prognostic value of AQP3 protein expression
in stage pT1 UBC patients. Despite numerous previous
attempts to identify clinical and histopathological prog-
nostic parameters, Shahin’s rule of each 30% of patientsdeveloping either never recurrence, recurring or even
dying of the disease is still valid [14].
Methods
Patient characteristics
Tumour specimens of 98 patients, who were diagnosed
between 2002 and 2009 with pT1 UBC by transurethral
resection of the bladder (TURB) and second resection
after 4–6 weeks were included in the present study. After
second resection (re-resection) all patients received adju-
vant instillation therapy with Bacillus Calmette-Guérin
(BCG). Progression to muscle-invasive disease resulted in
CX. TURB and all further treatment was carried out at a
single tertiary high-volume referral center according to
the European Association of Urology guidelines. Collec-
tion of tissue specimens had the approval of the local re-
search ethics committee and full informed patient
consent.
We retrospectively reviewed the histopathological and
clinical data of all patients in relation to tumour recur-
rence, disease progression, and cancer-specific survival.
Median follow-up was 31 months (range: 5–85 months).
Histopathological assessment
All bladder tumours were evaluated using the TNM classi-
fication [15] and given recent findings that the WHO clas-
sification of 1973 is superior to later versions in terms of
prognosis of non muscle-invasive bladder cancer patients,
we used the WHO 1973 classification for further analysis
[16,17]. Histopathological assessment was performed by
two expert uropathologists (A.H., F.H.).
Immunohistochemical assessment and analysis
Surgical samples were fixed in 10% formalin, dehydrated
and embedded in paraffin wax. Dewaxed 4μm tissue sec-
tions were subjected to antigen retrieval by boiling for 10
min in tris-ethylenediaminetetraacetic acid (Tris-EDTA;
pH 9) before labelling with titrated primary antibody
(polyclonal anti-AQP3, host: rabbit, antigen: human
AQP3, dilution 1:2000, Abcam, USA) for 16h at 4°C. Sec-
tions of normal urothelium within the TURB specimen
served as internal control. In additon, positive control tis-
sues of normal human urothelium known to express the
antigen and negative controls in which the primary anti-
body was omitted were included in all experiments to en-
sure the immunohistochemistry was performed correctly.
Evaluation of the slides was performed without know-
ledge of patient-related data exactly as previously
described [11,13]. Expression of AQP3 was visualised on a
Primo Star microscope (Carl Zeiss Microimaging, Jena,
Germany) under 4, 20, 40 and 100-fold magnification
(Figure 1). Tumours were classified as AQP3-negative
only in case of complete lack of immunoreactivity within
the complete tumour and simultaneous unequivocal
Figure 1 Examples of various patterns of AQP3. Homogeneous, cell membrane-associated expression of AQP3 in a low-grade papillary
tumour (top left, 10-fold magnification). Regular expression in the basal and suprabasal, but not superficial cell layers in a section of normal
human ureter (top right, 40-fold magnification). Heterogeneous expression of AQP3 in a high-grade pT1 tumour (bottom left, 40-fold
magnification). Lack of expression in another pT1G3 UBC specimen (bottom right, 10-fold magnification).
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each sample. Accordingly, partial expression, i.e. a tumour
exhibiting even small AQP3-immunoreactive areas, was
classified as AQP3 positive. Tumour specimens of a total
of 87 patients were eligible for immunohistochemistry.
The remaining 11 patients were excluded from the ana-
lysis due to insufficient amount of tumour tissue (n=4),
technical reasons (n=7), or loss of follow-up.
Statistical analysis
SPSS version 19.0 (SPSS Inc., Chicago, IL, USA) was used
for statistical analysis. We compared different patient
characteristics and clinicopathological parameters in re-
lation to the aquaporin 3 protein expression status of the
study patients by Fisher’s exact test. Multivariate Cox re-
gression analysis was used to demonstrate the potentialclinical value of AQP3 expression and other clinico-
pathological parameters for recurrence, progression and
cancer-specific survival. Recurrence-free, progression-
free and cancer-specific survival rates were calculated by
Kaplan-Meier analysis and Log rank test. Values <0.05
were considered statistically significant.
Results
Histopathological assessment
The median age of the 87 patients was 70 years (range
41–98 years, 83% male). 86% of patients presented with
an initial diagnosis of stage pT1 UBC. Patient-related
and histopathological data are summarized in Table 1.
There was no statistically significant difference with re-
gard to clinical and pathological parameters between
AQP3+ and AQP3- tumours.
Table 1 Patient charcateristics and clinicopathological parameters in relation to aquaporin 3 protein expression status
Parameter Total (%) AQP3 positive (%) AQP3 negative (%) p value
Number of patients 87 (100.0) 51 (58.6) 36 (41.4)
Gender
Female 15 (17.2) 7 (46.7) 8 (53.3) p=0.227
Male 72 (82.8) 44 (61.1) 28 (38.9)
Age
median age (years) 70 ±11.5 68 ±12.6 73 ±9.3 p=0.095
age range (years) 41-98 41-98 50-88
History
first diagnosis of UBC 75 (82.8) 43 (57.3) 32 (42.7) p=0.390
recurrent tumour 12 (17.2) 8 (66.7) 4 (33.3)
WHO grading 1973
pT1G2 15 (17.2) 8 (53.3) 7 (46.7) p=0.429
pT1G3 72 (82.7) 43 (59.7) 29 (40.3)
Cofactors
associated CIS 36 (41.4) 20 (55.6) 16 (44.4) p=0.394
multifocal tumours 17 (19.5) 11 (64.7) 6 (35.3) p=0.388
tumour size ≥3cm 41 (47.1) 27 (65.9) 14 (34.1) p=0.141
BCG instillations
≤ 6 instillations 68 (78.2) 42 (61.8) 26 (38.2) p=0.194
> 6 instillations 19 (21.8) 9 (47.4) 10 (52.6)
AQP3 aquaporin 3 protein; BCG Bacillus Calmette-Guérin; CIS carcinoma in situ; UBC urothelial bladder carcinoma; WHO world health organisation.
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Following diagnosis of stage T1 UBC patients underwent
instillation therapy with BCG with a median number of 6
instillations (range: 5–12 instillations). A total of 12 instil-
lations, as recommended by the EAU guidelines, were
completed by 19% of patients only due to irritative symp-
toms or low patient’s compliance. 23% of the patients had
tumour recurrence, half of whom (55%) developed tumour
progression (stage ≥pT2). All patients with recurrent dis-
ease underwent cystectomy. All patients who developed
muscle-invasive disease were excluded from the study.
Expression of AQP3 in relation to clinicopathological
parameters
59% of patients were shown to exhibit AQP3-positive
tumours, whereas 41% of patients and tumours, respect-
ively, did not express the marker. Marker expression was
independent of age, gender, patient history regarding
UBC, WHO grading and histopathological cofactors
such as carcinoma in situ (CIS), multifocal tumours and
tumour size ≥3cm as well as the number of BGC instilla-
tions (see Table 1).
Kaplan-Meier analysis of AQP3 expression in relation to
prognosis
1-, 2- and 4-year recurrence-free survival (RFS) was
90%, 79% and 22% in patients exhibting AQP3-negativetumours compared to 80%, 77% and 60% in patients
with AQP3-positive tumours. This difference was not
statistically significant (p=0.994). 1-, 2- and 4-year pro-
gression-free survival (PFS) was 97%, 86% and 20% in
patients with AQP 3-negative tumours and statistically
significantly worse compared to 98%, 98% and 72% in
patients exhibiting AQP3+ tumours (p=0.02). By con-
trast, 1-, 2- and 4-year cancer-specific survival (CSS)
showed no differences between AQP3+ (98%, 94% and
79%) and AQP3- (100%, 83%, 83%) tumour status
(p=0.762). Kaplan-Meier curves of RFS, PFS and CSS in
relation to AQP3 expression is illustrated in Figure 2.
Multivariate Cox regression analysis of clinicopathological
parameters and AQP3 expression in relation to prognosis
Multivariate Cox regression analyses for RFS, PFS and
CSS revealed statistically significant differences between
AQP3 positive and negative tumours in relation to PFS.
Loss of AQP3 was independently associated with a
worse PFS (HR 7.58, CI 1.29 – 44.68; p=0.025). Results
are shown in Table 2.
Discussion
Stage pT1 urothelial bladder carcinoma continues to be
a challenging tumour entity for urologists due to unpre-
dictable clinical courses. While about one third of
patients never experience tumour recurrence, at least
Figure 2 Kaplan-Meier analysis of recurrence-free (RFS) (a), progression-free (PFS) (b) and cancer-specific survival (CSS) (c) in relation
to aguaporin 3 expression in stage T1 urothelial bladder carcinoma. While the lower RFS of AQP3 negative patients did not reach statistical
significance, loss of AQP3 was associated with a statistically significantly worse PFS. There was no statistically significant difference in outcome
regarding CSS.
Otto et al. BMC Cancer 2012, 12:459 Page 5 of 8
http://www.biomedcentral.com/1471-2407/12/459one third requires radical cystectomy for progression to
muscle-invasive disease and the remaining 30% of
patients ultimately die of UBC [14].
Numerous research groups worldwide have scrutinized
a wide array of parameters to identify prognostic factors
that may help to predict tumour progression in stage pT1
UBC [18-24]. Among these parameters grading appears to
constitute the most powerful prognostic histopathologicalfeature. In their analysis of a large collective of 310 stage
pT1 UBC patients, Otto et al. only recently were able to
show that tumour grading, specifically the distinction be-
tween grade 2 and 3 tumours as classified by the WHO
classification of 1973, was the most consistent and reliable
predictor in respect to prognosis [16]. Moreover, a series
of immunohistochemical investigations into the prognos-
tic value of various proteins expressed by UBC was
Table 2 Multivariate Cox regression analysis of clinicopathological parameters and aquaporin 3 protein expression by
the tumour regarding recurrence free (a), progression-free (b) and cancer-specific survival (c) in stage T1 urothelial
bladder carcinoma
HR (CI 95%) p-value
a.
Gender female vs. male 0.50 (0.11 – 2.29) 0.372
Age per year 1.01 (0.97 – 1.05) 0.770
Recurrent disease yes vs. no (initial finding) 0.58 (0.10 – 3.50) 0.552
Grading WHO 1973 G3 vs. G2 1.08 (0.25 – 4.67) 0.916
Associated CIS yes vs. no 1.58 (0.63 – 3.97) 0.328
Focality multifocal vs. unifocal 0.33 (0.07 – 1.65) 0.177
Tumour size ≥3cm vs. <3cm 0.68 (0.25 – 1.92) 0.485
BCG instillations ≤6 vs. >6 0.77 (0.23 – 2.57) 0.667
AQP3 negative vs. positive expression 0.81 (0.29 – 2.25) 0.552
b.
Gender female vs. male 0.42 (0.03 – 5.27) 0.500
Age per year 1.01 (0.95 – 1.08) 0.697
Recurrent disease yes vs. no (initial finding) 4.08 (0.24 – 69.74) 0.332
Grading WHO 1973 G3 vs. G2 0.71 (0.28 – 1.79) 0.469
Associated CIS yes vs. no 1.40 (0.28 – 7.12) 0.683
Focality multifocal vs. unifocal constant 0.976
Tumour size ≥3cm vs. <3cm 2.64 (0.30 – 22.97) 0.380
BCG instillations ≤6 vs. >6 constant 0.977
AQP3 negative vs. positive expression 7.58 (1.29 – 44.68) 0.025
c.
Gender female vs. male constant 0.972
Age per year 1.03 (0.97 – 1.09) 0.338
Recurrent disease yes vs. no (initial finding) constant 0.999
Grading WHO 1973 G3 vs. G2 constant 0.975
Associated CIS yes vs. no 0.79 (0.18 – 3.46) 0.756
Focality multifocal vs. unifocal constant 0.976
Tumour size ≥3cm vs. <3cm 2.98 (0.35 – 24.86) 0.316
BCG instillations ≤6 vs. >6 constant
AQP3 negative vs. positive expression 1.16 (0.26 – 5.15) 0.849
Reference in italics; p-values <0.05 are indicated in bold; AQP3 aquaporin 3 protein; BCG Bacillus Calmette-Guérin; CI confidence interval; CIS carcinoma in situ; HR
hazard ratio; WHO world health organisation.
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ings. In a cohort of 175 patients, 19% of whom diagnosed
with pT1G3 UBC, Rodriguez Alonso and associates iden-
tified over-expression of tumour suppressor protein p53
by the tumour as prognostic factor. Overexpression of p53
and ki67 alongside CIS, multifocality and solid bladder
tumours were associated with a worse progression-free
survival in multivariate analysis [25]. Lopez-Beltran et al.
were able to demonstrate a prognostic value of different
biomarkers in relation to patient survival. In a total of 51
patients consisting of pT1G3 tumours, expression of p53
alongside other cell cycle regulators such as cyclin D1 andcyclin D3 showed prognostic significance for PFS in multi-
variate analysis [26]. By contrast, Park et al. were unable
to find any prognostic value for seven markers including
p53 and ki67 in 61 patients with pT1G3 UBC [27].
Our previous finding of AQP3 transcript and protein
expression in normal human urothelium and cultured
urothelial cells prompted us to investigate expression and
potential significance in diseased urothelium including
urothelial cancer [11,13]. In a preliminary analysis of
AQP3 expression in tumour specimens of various stages
of UBC, we demonstrated loss of AQP3 protein expres-
sion in muscle-invasive disease whereas pTa specimens
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note that 40% of stage pT1 UBC tumours exhibited loss of
AQP3 protein expression [13]. Hence, we concluded that
AQP3 might constitute a prognostic marker for progres-
sion to muscle-invasive disease.
Our present data indicate a statistically significantly
worse PFS in patients in whom immunohistochemistry
revealed loss of AQP3 expression. This finding was con-
firmed by multivariate Cox regression analysis. By con-
trast, recurrent disease was independent of the AQP3
expression status. Taking both our present and previous
findings into account, we hypothesize that expression of
AQP3 in stage pT1 UBC is pathogenetically associated
with non-muscle-invasive disease while loss of AQP3
may be part of a molecular program associated with pro-
gression to muscle-invasive UBC [13]. Moreover, abnor-
malities of chromosome 9p, where the AQP3 gene is
located, are frequently present in UBC, adding further
presumptive evidence for a role of AQP3. However, such
hypotheses have to be addressed in further studies aimed
at elucidating the biological significance of AQP3 ex-
pression in UBC.
The pro-tumourigenic effect of a loss of AQP3 has
been investigated in previous studies on other tumour
entities. Knockdown of AQP3 expression for instance
has been shown to be associated with increased migra-
tion and proliferation of gastric cancer cell lines [12]. In
contrast, Kuseyama et al. found a high level of expres-
sion of AQP3 in oral and esophageal squamous cell car-
cinomas (SCC) [28]. Xu and associates investigated the
effect of AQP3 on matrix metalloproteinase in human
gastric carcinoma cells and concluded that AQP3 may
be a promising drug target [29]. In the field of urological
neoplasms, Ismail et al. provided evidence that prostate
cancer cell lines in vitro become more sensitive to cryo-
therapy after inhibiting AQP3 by mercuric chloride and
AQP3 siRNA [30].
Although the present study did not investigate the
underlying molecular mechanisms of AQP expression in
urothelial carcinoma, our findings suggest that AQP3 may
be an independent predictor of tumour progression from
stage pT1 towards stage pT2 tumours. This finding may
be of clinical value in that patients exhibiting loss of ex-
pression of AQP3 in their TURB specimens could benefit
from aggressive surgical treatment in the form of early
cystectomy. However, we do not attempt to over-interprete
our findings. The retrospective design of the study and the
distinction between AQP3-positive versus AQP3-negative
tumours may be oversimplistic. A detailed analysis of the
various expression patterns of AQP3 in tumours by scoring
both the labeling intensity and the proportion of positively-
labeled tumour areas were not performed due to the low
number of AQP3-positive tumours (n=51). The lack of
such subanalyses is undoubtedly a limitation of the presentstudy. Future work analyzing an appropriate number of
AQP3-positive tumours is required to address this import-
ant aspect. Moreover, investigations into the molecular
mechanisms of AQP3 expression in urothelial carcinoma
are required to understand its role in the pathogenesis
of UBC.
Conclusions
The present study is the first to investigate a larger pa-
tient cohort of pT1 urothelial bladder carcinomas for
AQP3 protein expression. Lack of AQP3 protein expres-
sion in pT1 tumours was shown to be associated with
progression towards muscle-invasive disease. By con-
trast, tumour recurrence was independent of AQP3 ex-
pression. Importantly, this association was independent
of other clinicopathological parameters. We conclude
that AQP3 expression could be used to help stratify the
behavior of patients with pT1 UBC.
Our findings underline the importance of investigating
expression and function of AQPs beyond water and sol-
ute transport in normal and neoplastic urothelium. Fur-
ther studies into the molecular mechanisms of AQP3
expression as well as prospective multicentre studies are
to be awaited before valid conclusions can be drawn
from our present findings.
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